Next Article in Journal
Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection
Next Article in Special Issue
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
Previous Article in Journal
A Multidisciplinary Research Agenda for Understanding Vaccine-Related Decisions
Previous Article in Special Issue
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination
Open AccessArticle

Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques

Department of Microbiology Diagnostics and Virology, Statens Serum Institut, Copenhagen 2300, Denmark
Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam 1105, The Netherlands
Division of Immuno-Virology, Institute of Emerging Diseases and Immuno Therapies, CEA, Fontenay aux Roses 92260, France
Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
San Raffaele Scientific Institute, Milan 20123, Italy
Department of Laboratory Medicine, Lund University, Lund 22184, Sweden
Biomedical Department, Virology Unit, Institute of Tropical Medicine, Antwerp 2000, Belgium
Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark, Odense 5230, Denmark
Author to whom correspondence should be addressed.
Member of the NGIN consortium. Other members of the group are listed in the acknowledgment.
Vaccines 2013, 1(3), 305-327;
Received: 16 May 2013 / Revised: 5 July 2013 / Accepted: 10 July 2013 / Published: 19 July 2013
(This article belongs to the Special Issue DNA Vaccines)
HIV-1 DNA vaccines have many advantageous features. Evaluation of HIV-1 vaccine candidates often starts in small animal models before macaque and human trials. Here, we selected and optimized DNA vaccine candidates through systematic testing in rabbits for the induction of broadly neutralizing antibodies (bNAb). We compared three different animal models: guinea pigs, rabbits and cynomolgus macaques. Envelope genes from the prototype isolate HIV-1 Bx08 and two elite neutralizers were included. Codon-optimized genes, encoded secreted gp140 or membrane bound gp150, were modified for expression of stabilized soluble trimer gene products, and delivered individually or mixed. Specific IgG after repeated i.d. inoculations with electroporation confirmed in vivo expression and immunogenicity. Evaluations of rabbits and guinea pigs displayed similar results. The superior DNA construct in rabbits was a trivalent mix of non-modified codon-optimized gp140 envelope genes. Despite NAb responses with some potency and breadth in guinea pigs and rabbits, the DNA vaccinated macaques displayed less bNAb activity. It was concluded that a trivalent mix of non-modified gp140 genes from rationally selected clinical isolates was, in this study, the best option to induce high and broad NAb in the rabbit model, but this optimization does not directly translate into similar responses in cynomolgus macaques. View Full-Text
Keywords: DNA vaccine; HIV-1; animal models; envelope; neutralizing antibodies DNA vaccine; HIV-1; animal models; envelope; neutralizing antibodies
Show Figures

Figure 1

MDPI and ACS Style

Borggren, M.; Vinner, L.; Andresen, B.S.; Grevstad, B.; Repits, J.; Melchers, M.; Elvang, T.L.; Sanders, R.W.; Martinon, F.; Dereuddre-Bosquet, N.; Bowles, E.J.; Stewart-Jones, G.; Biswas, P.; Scarlatti, G.; Jansson, M.; Heyndrickx, L.; Grand, R.L.; Fomsgaard, A. Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines 2013, 1, 305-327.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop